About Protembis
Protembis is a company based in Aachen (Germany) founded in 2013 by Karl Von Mangoldt. Protembis has raised $45.17 million across 5 funding rounds from investors including Abiomed, European Investment Bank and BMBF. Protembis offers products and services including ProtEmbo Cerebral Protection System. Protembis operates in a competitive market with competitors including Claret Medical, Emboline, Synaptive Medical, Filterlex Medical and Keystone Heart, among others.
- Headquarter Aachen, Germany
- Founders Karl Von Mangoldt
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Protembis Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45.17 M (USD)
in 5 rounds
-
Latest Funding Round
$21.67 M (USD), Debt – Venture
Jul 30, 2024
-
Investors
Abiomed
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Protembis
Protembis offers a comprehensive portfolio of products and services, including ProtEmbo Cerebral Protection System.
Protects brain from injury during TAVR procedures effectively.
People of Protembis
Unlock access to complete
Unlock access to complete
Funding Insights of Protembis
Protembis has successfully raised a total of $45.17M across 5 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $21.67 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Protembis
Protembis has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Abiomed, European Investment Bank and BMBF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Early stage investments in life sciences are facilitated by XGEN Venture.
|
Locked | Locked | Locked | |
|
TechVision Fonds is engaged in early-stage venture capital investments.
|
Locked | Locked | Locked |
Investor details for Protembis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Protembis
Investment portfolio details for Protembis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Protembis
Detailed financials for Protembis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Protembis Comparisons
Peer comparison for Protembis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Protembis
Protembis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Claret Medical, Emboline, Synaptive Medical, Filterlex Medical and Keystone Heart, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cerebral vascular protection systems for endovascular procedures are developed.
|
|
| Locked | Locked | Locked |
Aortic embolic protection devices are developed for cardiovascular procedures.
|
|
| Locked | Locked | Locked |
Planning and imaging solutions for neurosurgery are developed.
|
|
| Locked | Locked | Locked |
Developer of an embolic protection device
|
|
| Locked | Locked | Locked |
Embolic cerebral protection devices
|
Detailed competitors of Protembis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Protembis
Complete news archive for Protembis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protembis
Protembis was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Protembis is headquartered in Aachen, Germany. It is registered at Aachen, North Rhine-westphalia, Germany.
Protembis is a funded company, having raised a total of $45.17M across 5 funding rounds to date.
Protembis was founded in 2013 and is based in Aachen, Germany. Operations are centered in the medical device sector, where an implantable filter system is produced for use during minimally invasive cardiac surgeries involving the left heart. The device is introduced into the aortic arch to block embolic particles from reaching the cerebral vasculature, thereby reducing stroke risk. Focus remains on cerebral protection technologies for surgical applications.
Protembis's top competitors include Synaptive Medical, Emboline and Claret Medical.
Protembis offers ProtEmbo Cerebral Protection System.
Protembis has 9 investors. Key investors include Abiomed, European Investment Bank, BMBF, Geratherm Medical AG, and Segulah Medical Acceleration.